BARDA (Biomedical Advanced Research and Development Authority) · · Solicitation: RFP
ImmuneChip+
BARDA solicits proposals under Area of Interest #10, ImmuneChip+, in its Broad Agency Announcement BAA-23-100-SOL-00004. The area funds advanced microphysiological systems and tissue-chip technologies that integrate human tissue models with immune components for testing medical countermeasures against CBRN and pandemic threats. Offerors follow a staged process of a pre-submission call, a Quad Chart and Market Research Abstract, and then a full proposal by invitation, submitted through the BARDA Digital Resources Portal. The solicitation states a submission deadline of 2028-09-25 at 4:30pm Eastern Time unless an Area of Interest states otherwise. The BARDA BAA page lists ImmuneChip+ as AOI 10.0 among its current Areas of Interest.
Who can apply
- Eligibility
No separate eligibility field is recorded. Check the program summary and the funder's terms.
- Location
No separate location field is recorded. Check the program summary and the funder's terms.
- Funding
No separate funding field is recorded. Check the program summary and the funder's terms.
Funding classification
- Instrument
No separate instrument field is recorded. Check the program summary and the funder's terms.
- Capital form
No separate capital form field is recorded. Check the program summary and the funder's terms.
- Allocation method
No separate allocation method field is recorded. Check the program summary and the funder's terms.
- Selection
No separate selection field is recorded. Check the program summary and the funder's terms.
Round history
| Round | Window | Size | Source |
|---|---|---|---|
| BAA-23-100-SOL-00004 open period | Deadline: September 25, 2028Deadline ahead | Not stated | everglade.com |
Past rounds stay on the page, so you can see how often this program opens.
Funding evidence
Detailed funding records are not yet recorded for this program.
Read the program’s recorded facts and sourcesSources
Awards
none linkedNo award records linked to this profile yet.